Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8552W HIGH $2.23
Volume
206.64 K
Value Traded
1.15 M
Short % Float
3.72%
Days to Cover
1.1
+10.22%Week
-1.31%1 Month
-1.31%3 Month
+16.15%6 Month
-52.87%5 Year
-85.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
38.54 M
EPS (TTM)
-0.32
P/E Ratio
-
Ent. Value
35.75 M
Total Shares
25.53 M
Float Shares
24.89 M
Insiders
2.49%
Institutions
9.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NNVC Catalyst Timeline
Dated clinical, regulatory and corporate events for NanoViricides, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NanoViricides, Inc.
128Total events
13Upcoming
7Tier-1 (high impact)
2008 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment UpdateNV-387Trial
Phase IIA Ebola trial of NV-387 oral gummies progressing well and enrolling
Ebola Bundibugyo virus infectionsource ↗
●Quarterly UpdateCorporate
NanoViricides filed Annual Report on Form 10-K for FY ending June 30, 2026
●Trial InitiationNV-387Trial
NV-387 entered Phase II clinical trial for Ebola BDBV Disease in DRC
Ebola Bundibugyo Virus (BDBV) Diseasesource ↗
▲First Patient DosedNV-387Trial
NV-387 Phase II Ebola trial began enrolling and dosing patients in DRC
Bundibugyo Ebolavirus and other Ebola virusessource ↗
●Enrollment UpdateNV-387Trial
Enrollment began in Phase IIA part of Phase II trial of NV-387 Oral Gummies for Ebola
Bundibugyo Ebolavirus (BDBV) and other Ebola virusessource ↗
●Trial RegisteredNV-387Trial
NV-387 Phase II MPox trial registered in Pan African Clinical Trials Registry
Monkeypox (MPox)source ↗
◆First Patient DosedNV-387Trial
First Ebola patient dosing with NV-387 oral gummies anticipated next week
Bundibugyo Ebolavirus and other Ebola virusessource ↗
▲Trial Authorization (CTA / IND)NV-387Ex-US Regulatory
ACOREP regulatory approval to begin Phase II Ebola trial of NV-387 Oral Gummies
Bundibugyo Ebolavirus and other Ebola virusessource ↗
●Timing GuidanceNV-387Presentation
NV-387 Oral Gummies shipped to and received at clinical trial site in Ituru province
Bundibugyo Ebolavirus and other Ebola virusessource ↗
◆Trial InitiationNV-387Trial
Phase II clinical trial of NV-387 Oral Gummies in Ebola scheduled to start next week in DRC
Bundibugyo Ebolavirus and other Ebola virusessource ↗
▲Enrollment UpdateNV-387Trial
Phase II Ebola trial of NV-387 began enrollment
Ebola virus diseasesource ↗
▲Rare Pediatric DiseaseNV-387Designation
FDA grants Rare Pediatric Disease Drug designation to NV-387 for measles
Measlessource ↗
▲Orphan Drug DesignationNV-387Designation
FDA grants Orphan Drug Designation to NV-387 for measles
Measlessource ↗
▲Trial Authorization (CTA / IND)NV-387Ex-US Regulatory
ACOREP DRC approval of Phase II trial of NV-387 Oral Gummies for Ebola
Ebola virus diseasesource ↗
●First Patient DosedMBP134Trial
First patient received MBP134 antibody cocktail infusion in PARTNERS trial
Ebola virus diseasesource ↗
●Trial InitiationMBP134Trial
PARTNERS clinical trial started evaluating MBP134 and remdesivir infusions
Ebola virus diseasesource ↗
●Trial Authorization (CTA / IND)NV-387Ex-US Regulatory
Application submitted for Phase II trial of NV-387 for Ebola
Ebola virus diseasesource ↗
▲Rare Pediatric DiseaseNV-387Designation
FDA granted RPDD designation for NV-387 for pediatric Measles
Measlessource ↗
▼Other Regulator MilestoneEx-US Regulatory
WHO declared Ebola outbreak a Public Health Emergency of International Concern
Ebola virus diseasesource ↗
▼Timing GuidancePresentation
WHO declared Ebola outbreak a Public Health Emergency of International Concern
Ebola virus diseasesource ↗
▲Orphan Drug DesignationNV-387Designation
NV-387 granted Orphan Drug Designation by US FDA for treatment of measles
Measlessource ↗
◆Rare Pediatric DiseaseNV-387Designation
Rare Pediatric Disease Drug designation application submitted for NV-387 for measles
Measlessource ↗
▲Orphan Drug DesignationNV-387Designation
FDA granted Orphan Drug Designation for NV-387 for Measles
Measlessource ↗
◆Orphan Drug DesignationNV-387Designation
Orphan Drug Designation application filed for NV-387 for MPox
MPoxsource ↗
●Orphan Drug DesignationNV-387Designation
Application submitted for Orphan Drug Designation for NV-387 for Measles
Measlessource ↗
▼Equity OfferingCorporate
Pricing of $6 million registered direct offering and concurrent private placement
▲Trial Authorization (CTA / IND)NV-387Ex-US Regulatory
ACOREP DRC approval of Phase II trial of NV-387 Oral Gummies for Mpox
Mpoxsource ↗
◆Oral PresentationPresentation
NanoViricides presenting at Inaugural EF Hutton Global Conference
▲Preclinical PoCNV-CoV-2-RPreclinical
PK study shows improved remdesivir stability and accumulation with NV-CoV-2-R in rats
COVID-19source ↗
▲Partnership / LicenseCorporate
Completed licensing for human Coronavirus field from TheraCour Pharma
human Coronavirus infectionssource ↗
▲Patent GrantedIP / Competition
PCT patent application filed for NV-CoV-2 and NV-CoV-2-R
COVID-19source ↗
●Development Candidate NominationPreclinical
Close to declaring a clinical candidate for SARS-CoV-2
COVID-19source ↗
●Preclinical PoCPreclinical
Preclinical testing of remdesivir-encapsulated nanoviricide
COVID-19source ↗
▼Equity OfferingCorporate
Pricing of $10.2 million registered direct offering of 1,400,000 shares at $7.30 per share
▲Management ChangeCorporate
Honorable Todd Rokita joins Board of Directors as independent director
▼Equity OfferingCorporate
Closed underwritten public offering of common stock with gross proceeds of $8.625 million
●IND SubmissionHHV-101IND
IND filing for NV-HHV-101 shingles drug candidate expected after COVID-19 IND
shinglessource ↗
▲Pre IND MeetingHHV-101FDA Meeting
Pre-IND application filed and favorable responses received
shingles rashsource ↗
▼Equity OfferingCorporate
Filed for underwritten common-stock-only secondary public offering on Form S-1
Past FDA Catalysts and PDUFA Decisions
How NNVC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NNVC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Diwan AnilDirector, Officer (President) | Disposition | -94,471 | $0.00 | 08/08/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in NNVC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NNVC for Q2 2026. | ||||
NNVC Institutional Ownership Trends
NNVC Short Interest
Shares sold short, counted twice a month.
3.72%
Short % of Float
of tradable shares sold short
925.5K
Shares Sold Short
+57.5% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
879.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NNVC ranks across every disease it competes in
Competitive Position is a premium feature
See how NNVC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNNVC News
NNVC▲ +2%today
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
NanoViricides announced that its antiviral drug NV-387 showed excellent safety and tolerability in a juvenile mouse study. This study supports potential pediatric clinical trials for treating Ebola, Mpox, and Measles in children. NV-387 is currently in Phase II trials for Ebola and Mpox in the Democratic Republic of Congo.
Read more →NNVCPhase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides, Inc. reported positive progress in its Phase IIA clinical trial for NV-387 oral gummies, aimed at treating Ebola Bundibugyo virus. The trial evaluates various dosages for patients with different severity levels of the disease. Despite challenges such as high infection rates and patient withdrawal risks, NV-387 shows promise as a broad-spectrum antiviral treatment.
Read more →NNVCNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
NanoViricides, Inc. will present at NIBA's 153rd Investment Conference on October 7, 2026. The company is advancing its antiviral drug NV-387 into Phase II trials for Ebola and Mpox, addressing critical health needs. NV-387 is also being developed for Measles and shows effectiveness against various respiratory viruses. The ongoing Ebola outbreak has raised urgent concerns, with significant fatalities and economic implications.
Read more →NNVC▲ +13.3%on this newsshared move
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. is advancing its Phase II clinical trial for NV-387 Oral Gummies aimed at treating the Bundibugyo Ebolavirus in the Democratic Republic of Congo. The trial is designed to evaluate the tolerability of the drug's dosage regimen, with the aim of preparing for a larger efficacy trial. The current Ebola outbreak has escalated, with over 4,000 deaths reported, highlighting the urgent need for effective treatments.
Read more →NNVC▼ -13.3%on this news
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
NanoViricides, Inc. has filed its Annual Report, highlighting significant achievements in the development of NV-387, a broad-spectrum antiviral drug. The drug is currently in Phase II clinical trials for treating Mpox and Ebola in the Democratic Republic of Congo. Despite the promising advancements, the company faces challenges, including a growing Ebola outbreak and financial uncertainties.
Read more →NNVCClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
NanoViricides, Inc. has commenced enrollment and dosing for its Phase II clinical trial of NV-387 Oral Gummies to treat the Bundibugyo ebolavirus in the Democratic Republic of Congo. The trial aims to establish a safe dosing protocol and evaluate the drug's efficacy against Ebola. NV-387 is notable as the only oral treatment currently in clinical trials, with previous studies indicating its potential effectiveness compared to existing therapies.
Read more →NNVCPhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
NanoViricides has initiated a Phase II clinical trial for NV-387, an antiviral treatment for Monkeypox, in the Democratic Republic of Congo. The trial aims to evaluate the drug's efficacy and safety compared to standard care. Led by Prof. Vivi Maketa, the study is crucial as there are currently no approved treatments for Monkeypox. The trial's success could position NV-387 as a vital tool in pandemic response.
Read more →NNVCClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NanoViricides, Inc. is set to begin a Phase II clinical trial for NV-387, an oral drug aimed at treating the Bundibugyo ebolavirus in the Democratic Republic of Congo. The trial is crucial as the region faces a severe Ebola outbreak with a high fatality rate. NV-387's oral formulation offers advantages over infusion treatments, which are less scalable and pose risks to healthcare workers. The company expresses hope for NV-387's effectiveness based on prior studies.
Read more →NNVCClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
NanoViricides, Inc. has registered a Phase II clinical trial for NV-387 Oral Gummies as a treatment for the Bundibugyo ebolavirus in the Democratic Republic of Congo. The trial, led by Prof. Patrick de Marie Chimusa Katoto, aims to evaluate the safety and efficacy of the drug amidst the largest Ebola outbreak recorded. The trial is expected to begin patient dosing shortly, with significant urgency due to the outbreak's rapid spread and high fatality rates.
Read more →NNVCWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides is preparing to initiate Phase II clinical trials for NV-387, a broad-spectrum antiviral drug aimed at treating measles, amid rising measles cases in the USA and globally. The drug has demonstrated promising in vivo efficacy against the measles virus and has received FDA's Rare Pediatric Disease Drug Designation. The company is currently drafting a clinical trial protocol for submission to the FDA.
Read more →NNVC▼ -14.9%on this news
NanoViricides Announces Pricing of ~$2 Million Registered Direct
NanoViricides, Inc. has announced a registered direct offering to raise approximately $2 million through the sale of common shares and accompanying warrants. This offering involves a single institutional investor and is scheduled to close around May 18, 2026, pending customary conditions. The company emphasizes its innovative antiviral, NV-387, which has received orphan drug designation, potentially benefiting from market exclusivity and cost offsets. However, the company acknowledges inherent risks related to market and regulatory uncertainties surrounding the completion of the offering.
Read more →NNVC▲ +15.4%on this news
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides, Inc. announced that its antiviral drug NV-387 has been granted Orphan Drug Designation by the US FDA for the treatment of Measles. This designation will expedite regulatory development and provide various incentives. NV-387 has shown strong efficacy in animal models against the Measles virus, which is critical as global cases rise. The company is also pursuing additional designations to enhance its development strategy.
Read more →NNVC▼ -7.9%on this news
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
NanoViricides, Inc. has filed for Orphan Drug Designation for NV-387 as a treatment for MPox with the FDA. If approved, this designation could provide various incentives, including tax credits and market exclusivity. NV-387 has demonstrated effectiveness in animal models and completed a Phase I clinical trial without adverse events. However, there are no approved treatments for MPox, and existing options have shown limited effectiveness.
Read more →NNVCNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides emphasizes the urgent need for broad-spectrum antivirals amid a severe influenza wave, particularly due to the ineffectiveness of current vaccines and antivirals. Their drug candidate NV-387 is designed to combat various respiratory viruses, including the new H3N2 variant, and shows superior efficacy compared to existing treatments. A Phase II clinical trial for NV-387 is planned, aiming to establish it as a first-line therapy for respiratory viral infections.
Read more →NNVC▼ -5.4%on this news· ran to -15% by day 3
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. has announced a registered direct offering and concurrent private placement aimed at raising approximately $6 million through the sale of shares at $1.68 each. The offering includes Series A and Series B warrants that will allow investors to purchase additional shares. The funds will be used for working capital and general corporate purposes, with the closing expected soon, subject to customary conditions. This move highlights NanoViricides' ongoing efforts to advance its antiviral drug development initiatives.
Read more →NNVCNanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
NanoViricides, Inc. will present at The Inaugural EF Hutton Global Conference in New York City on May 10, 2023. The conference will host key executives from various sectors to engage with institutional investors and media. As a clinical stage company specializing in antiviral therapies, NanoViricides aims to highlight its novel nanomedicine platform during this significant event. The conference is organized by EF Hutton, a global investment bank, providing an exclusive forum for companies to share their initiatives.
Read more →NNVC▲ +63.3%on this news
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug Shelton, Connecticut --
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Connecticut -- September 21, 2021 -- NanoViricides, Inc. (NYSE American: NNVC) (the "
Read more →NNVC▼ -12%on this news
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Shelton, Connecticut
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Shelton, Connecticut - September 14, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that
Read more →NNVCNanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA SHELTON, CONNECTICUT
Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA SHELTON, CONNECTICUT -- November 19, 2020 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that
Read more →NNVCNanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500
is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 CT / ACCESSWIRE / September 4, 2020/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral th
Read more →About NanoViricides, Inc.
Headquarters1 CONTROLS DRIVE, SHELTON, CT, 06484
Founded26-10-2005
BIOPHARMAWATCH ELITE PLUS
Trade the next NNVC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime